Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
307 studies found for:    Open Studies | "Prednisone"
Show Display Options
Rank Status Study
1 Recruiting PRednisone Plus EVerolimus in Patients With Metastatic Renal Cell Cancer After Failure of VEGFR -TKI
Condition: Metastatic Renal Cancer
Intervention: Drug: Prednisone + Everolimus
2 Recruiting Delayed Release Prednisone in PMR
Condition: Polymyalgia Rheumatica
Interventions: Drug: Delayed-Release (DR) Prednisone;   Drug: Immediate Release (IR) Prednisone
3 Recruiting The Assessment of Prednisone In Remission Trial - Centers of Excellence Approach
Condition: Granulomatosis With Polyangiitis
Interventions: Drug: Prednisone 5 mg/day;   Drug: Prednisone 0 mg/day
4 Recruiting The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric Approach
Conditions: Granulomatosis With Polyangiitis;   Wegener Granulomatosis;   Vasculitis
Interventions: Drug: 5 mg prednisone;   Drug: 0 mg prednisone
5 Recruiting Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy
Condition: IgA Nephropathy
Interventions: Drug: prednisone plus cyclophosphamide;   Drug: Prednisone alone
6 Recruiting Use of a Single Dose of Oral Prednisone in the Treatment of Cellulitis
Condition: Cellulitis
Interventions: Drug: Prednisone;   Drug: Placebo
7 Recruiting Long-term Prednisone Use for End-stage Heart Failure
Conditions: Heart Failure;   Hyperuricemia
Intervention: Drug: prednisone
8 Not yet recruiting Vaginal Prednisone Administration for Prevention of Adrenal Crisis
Condition: Adrenal Insufficiency
Intervention: Drug: 100mg prednisone suppository
9 Recruiting Prednisone in Chronic Rhinosinusitis Without Nasal Polyps
Conditions: Sinusitis;   Chronic Rhinosinusitis
Interventions: Drug: Prednisone;   Drug: Placebo
10 Recruiting Evaluation of the Discontinuation of Maintenance Corticosteroid Treatment in Quiescent Systemic Lupus
Condition: Systemic Lupus Erythematosus
Intervention: Drug: prednisone discontinuation
11 Recruiting Study of Carfilzomib Weekly Plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Carfilzomib
12 Recruiting Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis
Conditions: Lung Cancer;   Lung Metastases
Interventions: Drug: Nintedanib;   Drug: Prednisone;   Other: Placebo
13 Recruiting Prednisone for Heart Failure Patients With Hyperuricemia
Condition: Heart Failure, Hyperuricemia
Interventions: Drug: Prednisone;   Drug: Allopurinol
14 Recruiting Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
Condition: Langerhans Cell Histiocytosis
Interventions: Drug: Cytarabine;   Drug: Vinblastine/prednisone
15 Recruiting Phase 0/1 Biomarker and Pharmacodynamic Study of Roflumilast in Patients With Advanced B-Cell Hematologic Malignancies (CTRC# 13-0013)
Condition: Advanced B-cell Lymphoid Malignancies
Interventions: Drug: Prednisone;   Drug: Roflumilast
16 Not yet recruiting Integrative Medicine of IgA Nephropathy
Condition: Primary IgA Nephropathy
Interventions: Drug: WM (Shentong Granules);   Drug: Hormone (prednisone)
17 Recruiting Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Docetaxel;   Drug: Enzalutamide;   Drug: Prednisone
18 Recruiting Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Bendamustine, Bortezomib, Prednisone
19 Not yet recruiting Infliximab With Prednisone or Methylprednisolone With Prednisone Combination Treatment in Immune Related or Severe Diarrhea Patients Treated With Yervoy and/or Opdivo
Conditions: Renal Cell Carcinoma;   Melanoma;   Lung Cancer
Interventions: Drug: Infliximab + Prednisone;   Drug: Methylprednisolone + Prednisone
20 Recruiting A Study to Evaluate Steroid-free Treatment for Standard-Risk aGVHD (BMT CTN 1501)
Condition: Acute GVHD
Interventions: Drug: Sirolimus;   Drug: Prednisone

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.